We have extensive experience in the synthesis of Proteolysis Targeting Chimeras (PROTAC) and partial PROTAC for targeted protein degradation, including the development and functionalization of various E3-ligase ligands such as CRBN, VHL, MDM2 ,and cIAP1, some of them even in multi-gram scale. In addition to the synthesis of commercially available ligands, we are also experienced in developing novel structural analogues.
We also synthesize a large variety of linkers needed for the linkage of E3-Ligase ligands to the target-binding ligands, including PEG linkers, carbon-based chains, with a large variety of end functionalities including –NH2, –CO2H, –N3, –C≡CH, –CHO, –X and –OH to be connected with almost any active targets.
We have unique capabilities for tailor-made partial PROTACs, which are ready for rapid target linkage. We also have a series of E3-ligase ligands and linkers on our shelves.
Our in-house collection offers clients a quick and efficient way to jump-start their drug discovery programs and reach meaningful conclusions faster.
We complement our medicinal chemistry of PROTACs with a vast experience in the biology of protein degraders and comprehensive in vitro biology support, including various biological assays, DMPK and toxicology support.
Target Protein degradation is a process in which the protein of interest is degraded using E3 ubiquitin ligase and a chemical linker by polyubiquitination followed by proteasome degradation.
High target selectivity demonstrates high potencies, less toxic ,and minimizing the risk of developing resistance.
A targeting ligand (warhead) for the protein of interest and a ligand that recruits an E3 ubiquitin ligase connected via a carefully-chosen chemical linker (PROTAC). The resulting compound can induce formation of a ternary complex (the target, degradation compound and E3 ligase). The design of degrader compounds is critical to form an effective ternary complex.
The addition of ubiquitin to a substrate protein is called ubiquitination. Ubiquitination of target proteins involves a three-step enzymatic process, i.e., Activation, conjugation, and Ligation. Finally, polyubiquitinated proteins are recognized by the proteasome then degrades into small peptides by proteolysis.
Cellular Permeability and Target Affinity are the important factors to decide the effective binding of PROTAC with target protein and ubiquitination. These parameters play a crucial role in the designing of PROTAC molecules.
PROTACs regulate protein function by degrading target proteins instead of inhibiting them, providing more sensitivity to drug-resistant targets and a greater chance of affecting nonenzymatic functions. PROTACs have been proven to show better selectivity compared to classic inhibitors. It has attracted great attention both from academia and industry.
Catalytic in nature, targeted degradation and selectivity provide a niche for PROTAC applications in cancer diseases and immune disorders, viral infections, and neurodegenerative diseases.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.